These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 22028292)

  • 1. [Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
    Michels G; Erdmann E; Pfister R
    Dtsch Med Wochenschr; 2011 Nov; 136(44):2267-70. PubMed ID: 22028292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the role of roflumilast in chronic obstructive pulmonary disease?
    Lau C; Mehta AC; Hatipoglu U
    Cleve Clin J Med; 2017 Jan; 84(1):13-15. PubMed ID: 28084977
    [No Abstract]   [Full Text] [Related]  

  • 4. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
    Martínez FJ
    Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
    [No Abstract]   [Full Text] [Related]  

  • 5. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
    Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA
    Swiss Med Wkly; 2012; 142():w13628. PubMed ID: 22833385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
    Pinner NA; Hamilton LA; Hughes A
    Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic options in the management of COPD - focus on roflumilast.
    Antoniu SA
    Int J Chron Obstruct Pulmon Dis; 2011; 6():147-55. PubMed ID: 21468165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
    Yan JH; Gu WJ; Pan L
    Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roflumilast for COPD.
    Izquierdo JL; Aparicio J
    Drugs Today (Barc); 2010 Nov; 46(11):823-31. PubMed ID: 21225021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase-4 inhibition in COPD.
    O'Byrne PM; Gauvreau G
    Lancet; 2009 Aug; 374(9691):665-7. PubMed ID: 19716944
    [No Abstract]   [Full Text] [Related]  

  • 17. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
    Cazzola M; Picciolo S; Matera MG
    Expert Opin Pharmacother; 2010 Feb; 11(3):441-9. PubMed ID: 20102307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2011; 25(4):176-7. PubMed ID: 21654371
    [No Abstract]   [Full Text] [Related]  

  • 19. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
    Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
    Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Considerations for Roflumilast: A New Treatment for COPD.
    Kelly Freeman ML
    Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.